Enzo Biochem (NYSE:ENZ – Get Free Report) released its quarterly earnings results on Monday. The medical research company reported ($0.02) earnings per share for the quarter, Zacks reports. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.
Enzo Biochem Stock Performance
Shares of NYSE:ENZ opened at $0.47 on Tuesday. The company’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $0.87. Enzo Biochem has a 12-month low of $0.41 and a 12-month high of $1.30.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on shares of Enzo Biochem in a research report on Saturday. They set a “hold” rating on the stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Articles
- Five stocks we like better than Enzo Biochem
- What Do S&P 500 Stocks Tell Investors About the Market?
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
- Find and Profitably Trade Stocks at 52-Week Lows
- ARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?
- Roth IRA Calculator: Calculate Your Potential Returns
- Can TikTok Stock Picks Really Make You Rich?
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.
